Autolus Therapeutics plc (AUTL) research
Autolus Therapeutics plc- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.78
- As of
Autolus Therapeutics plc (AUTL): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-11.
As of . Source: SEC EDGAR filings for AUTL. Method and limitations.
Share the AUTL intelligence card
See the full AUTL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AUTL on one page. Preview it with sample data, then open it live with a free account.
Preview the AUTL dossierActive signals for AUTL
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 83% of AUTL (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +498% to AUTL (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 91% of AUTL (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 31.8%, EPS $-0.15 vs $-0.22 estimate
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 25.1% - EPS $-0.18 vs $-0.2404 estimate
FREE, NO ACCOUNT
Every signal on AUTL, as it fires
You are seeing 5 of 7 signals recorded on AUTL since 2026-05-26.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AUTL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 05280R100 · 2026Q2 | $3.2M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 05280R100 · 2026Q2 | $2M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 05280R100 · 2026Q2 | $1.1M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 05280R100 · 2026Q2 | $114K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AUTL
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
AUTL against its peers
AUTL's operating margin of -358.9% ranks in the 54th percentile of 13 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | AUTL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 75.4M USD | 4.6M USD | 75 | 17 |
| Operating margin | -358.9% | -585.2% | 54 | 13 |
| Net margin | -381.4% | -240.1% | 46 | 13 |
| Return on equity | -161.4% | -43.1% | 15 | 22 |
Peers (23): RGNX, ARVN, CTNM, PBYI, OVID, EPRX, ASMB, ALLO, OCS, ENTX, MNPR, CBIO, NGNE, DMAC, ALT, TECX, PRME, CAPR, PRTA, INDP, YDES, CTMX, VALN. Left out: DRUG (period gap), RLFTY (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (AUTL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow AUTL on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to AUTL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.